Patrys featured as one of Top 10 Best Healthcare Companies in Australia
0
Patrys has been featured as one of the Top 10 Best Healthcare Companies in Australia in Insights Care Magazine. CEO and MD,…
Draft GLP toxicology reports received
Patrys today announced that it has received positive draft reports for two recently completed Good Laboratory Practice (GLP) toxicology studies…
QUARTERLY ACTIVITIES REPORT & 4C | 31 March 2023
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31…
VIDEO | Proactive
Patrys’ CEO and MD, Dr James Campbell, spoke with Proactive’s Elisha Newell about the announcement of two new US patents for the Company’s…
Two New Patents Granted by US Patent and Trademark Organisation
Patrys’ deoxymab platform has been further strengthened by the granting of two new patents by the US Patent and Trademark…
Updated guidance for PAT-DX1 phase 1 clinical study
Patrys Limited (ASX: PAB), has advised that, based on recent updates from its Contract Development Manufacturing Organisation (CDMO) regarding the…
Preclinical data supports synthetic lethality application
A new preclinical study exploiting the novel ability of deoxymabs to enter the cell nucleus to disrupt the cell’s DNA…
Patrys Investor Newsletter | March 2023
Our latest Investor Newsletter is out now. Read the latest updates on progress towards our first in-human clinical trial of…
QUARTERLY ACTIVITIES REPORT & 4C
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31…
Patrys receives R&D Tax Incentive Refund
Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $3.35 million R&D Tax Incentive…